Experimental gene therapy aims to revive lung cancer treatment
NCT ID NCT04486833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the drug osimertinib (Tagrisso) in people with advanced EGFR-mutant non-small cell lung cancer whose cancer has stopped responding to osimertinib alone. The gene therapy delivers a tumor-suppressing gene to cancer cells. The trial has three parts: a dose-finding phase, an open-label phase, and a randomized phase comparing the combination to chemotherapy. About 158 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
quaratusugene ozeplasmid (Reqorsa) plus osimertinib (Tagrisso)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose current medication stops working.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. The gene therapy is experimental and may cause side effects or not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carle Cancer Institute
RECRUITINGUrbana, Illinois, 61801, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gabrail Cancer Center Research
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Markey Cancer Center
RECRUITINGLexington, Kentucky, 40536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Maryland Oncology Hematology
RECRUITINGRockville, Maryland, 20850, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Millennium Oncology
TERMINATEDHouston, Texas, 77090, United States
-
Rocky Mountain Cancer Centers
RECRUITINGLone Tree, Colorado, 80124, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Valley Hospital - Luckow Pavilion
RECRUITINGParamus, New Jersey, 07652, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Oncology Associates
RECRUITINGNorfolk, Virginia, 23502, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••